Oculocutaneous albinism (OCA) is a complex genetic disease with great clinical heterogeneity. Four different types of OCA have been reported to date (OCA1, OCA2, OCA3, and OCA4). MATP was recently reported in a single Turkish OCA patient as the fourth pathological gene, but no other patients with OCA4 have been reported. Here, we report the mutational profile of OCA4, determined by genetic analysis of the MATP gene in a large Japanese population with OCA. Of 75 unrelated patients that were screened, 18 individuals (24%) were identified as having OCA4; they harbored seven novel mutations, including four missense mutations (P58S, D157N, G188V, and V507L) and three frameshift mutations (S90CGGCCA-->GC, V144insAAGT, and V469delG), showing that MATP is the most frequent locus for tyrosinase-positive OCA in Japanese patients. We discuss the functional melanogenic activity of each mutant allele, judging from the relationship between the phenotypes and genotypes of the patients. This is the first report on a large group of patients with OCA4.

Diabetes mellitus is one of the most common chronic diseases and a major contributor to the development of cardiovascular diseases. It is due to a deficiency or a failure of normal action of insulin, which is responsible of the use of the sugar from the diet. The number of cases of non-insulin dependent diabetes mellitus has increased dramatically due to the changes in lifestyle, increasing prevalence of obesity, and ageing of populations. 1) In the year 2000, the number of diabetic patients was 151 million and is estimated to rise to 300 million by 2025. 2,3)The uses of natural drugs, such as plants and herbal remedies to treat diseases is very common in Asia and developing countries, where the population is linked with the use of traditional medicines, due to their efficiency or due the costs of the synthetic drugs and/or pharmaceuticals. One of the aims of phytochemists is to find the application of ethnomedicine in drug discovery. Moreover, WHO study groups emphasize strongly the optimal, rational uses of traditional and natural indigenous medicines (http://www.who.int/mediacentre/factsheets/fs134/en/). The leprosy gourd (bitter gourd, ayurveda name: karela), Momordica charantia L., a well known plant for its antidiabetic properties in Asia and some African countries, is among the candidates. Bitter and non-bitter cucurbitane triterpene aglycones and/or glycosides have been isolated from the plant. [4][5][6][7][8][9][10][11] The bitter principles so far reported have been characterized as momordicosides K and L, and momordicines I and II. 5,8) Interestingly, the four compounds have C-9 formyl, 7-OH or O-b-D-glucopyranosyl groups and are unsaturated at C-5, C-6. These features might be the structural requirement for the bitter taste and undoubtedly, the high content of saponins in the plant can be related to its taste.The constituents responsible for the glucose lowering activity are not yet well known even though over hundred scientific articles have described the phytochemical and pharmacological properties of the plant. 12,13) In the course of our phytochemical screening of medicinal plants aimed at finding the active principles for antidiabetic activities, eleven compounds (1-11) were isolated from the Indian bitter gourd sample. The structural elucidation of compounds 1-3 is reported and the major compounds (4 and 5) have been tested against the antidiabetic strain of male ddY mice. The objective of the present study is to find the relationship between Momordica charantia constituents and the antidiabetic properties of the plant. Results and DiscussionEffect of the Extracts on Diabetes Induced Mice The ether and ethyl acetate fractions of the water suspension of the bitter gourds methanol extract were tested for antidiabetic assay in mice. Oral administration of each fraction at 500 mg/kg (Figs. 3, 4, respectively) resulted marked hypoglycaemic effects comparable to glibenclamide (at 200 mg/kg).Isolation and Characterization of Constituents from the Active Extracts A combination of size exclusion and sil...

Objective. To evaluate whether matrix metalloproteinase 3 (MMP-3), a proteinase that is expressed in rheumatoid synovial tissue and shows potent activity in degrading the proteoglycan of cartilage, plays a pivotal role in the joint destruction seen in early rheumatoid arthritis (RA).Methods. In a prospective study of patients with early RA, the relationship between the serum concentration of MMP-3, as determined by a sandwich enzyme immunoassay system, and the progression of joint destruction in patients with early RA, as measured by the Larsen radiologic score, was investigated.Results. Serum MMP-3 levels were elevated in the RA patients compared with healthy controls, not only in the late stage, but also in the early stage of the disease in patients whose duration of RA was <4 months. The serum MMP-3 level at entry into the study had a strong correlation with the Larsen score at 6 months and 12 months after entry (r ‫؍‬ 0.58 and r ‫؍‬ 0.49, respectively). Similarly, the serum MMP-3 level at 12 months and 24 months after entry showed a positive association with the Larsen score in the subsequent 6-12 months. Suppression of the serum MMP-3 level in the first year led to a decline in joint damage in the second year.Conclusion. The serum concentration of MMP-3 is a useful marker for predicting bone damage in the early stage of RA, and the suppression of MMP-3 production may be an effective therapeutic approach for patients with early RA.

Our study has provided the first epidemiological data on Japanese patients with RA for the safety of TNF inhibitors compared to nonbiological DMARD for up to 1 year of treatment. Anti-TNF therapy was associated with a significantly increased risk for serious infections, compared to treatment with nonbiological DMARD.

Recently, we reported that serum concentration of IL-18 is strikingly high in patients with adult-onset Still's disease (AOSD). The aim of the present study was to screen for genetic polymorphisms in the human IL-18 (hIL-18) gene and to determine the association of polymorphisms with susceptibility to AOSD. We investigated the 6.7 kb region upstream of exon 2 of hIL-18 gene, in which a promoter activity had been reported. Sixteen AOSD patients, 144 rheumatoid arthritis (RA) patients and 92 healthy control individuals were studied. We found seven single nucleotide polymorphisms and a single 9 bp insertion which were frequently present in the AOSD patients. Three haplotypes including a unique combination of these polymorphisms were also determined. Of them, haplotype S01 contained all eight of these polymorphisms. The frequency of individuals carrying a diplotype configuration, ie a combination of two haplotypes, of S01/S01 was significantly higher in the AOSD patients than in the healthy controls (P ¼ 0.00059, Fischer's exact probability test, odds ratio [OR] ¼ 7.81, 95% confidence interval [95% CI] ¼ 2. 48-24.65) and the RA patients (P ¼ 0.015, Fischer's exact probability test, OR ¼ 4.0, 95% CI ¼ 1.39-11.54). We therefore conclude that possession of the diplotype configuration of S01/S01 is a major genetic risk factor for susceptibility to AOSD.